Value
5.4/10data confidence 100%| Component | Sub-score |
|---|---|
| Fwd P/E | 1.0 |
| PEG | 6.1 |
| Analyst target | 9.0 |
- ▸Forward P/E: 145.9x
- ▸PEG: 1.23
CELC · Why this verdict
Why Celcuity (CELC) is rated SELL
Updated
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
VerdictSELL
Overall score5.2/10
ConfidenceMEDIUM
MacroNEUTRAL
Thesis pillars
| Pillar | Expectation | Trend |
|---|---|---|
The entire investment thesis rests on a single drug candidate; a clinical failure, trial delay, or restrictive label outcome for this program would eliminate the primary source of expected value with no diversified asset base to sustain the business. Bear case | At least 2 pipeline programs reach Phase 2 or later within 8 quarters, reducing dependence on the lead candidate and providing an independent source of potential value. | →Stable |
| CounterDeep focus on a single, well-characterized candidate can accelerate development timelines and allows management to concentrate clinical and commercial resources where their conviction is highest; focused development in a well-defined indication is a strategic choice, and analysts covering the program have set a consensus target 83% above the current price. | ||
Free cash flow is negative, the Piotroski F-Score is only 3 out of 9, and there is no identified competitive moat — three conditions together meaning the business consumes capital without a demonstrated ability to generate durable returns, leaving the quality foundation extremely thin. Quality breakdown | Cash runway extends without dilutive financing for at least 6 consecutive quarters while the Piotroski F-Score rises above 5, signaling improving financial health. | →Stable |
| CounterPre-revenue clinical-stage companies are structurally loss-making; burn rates and low Piotroski scores are expected at this development stage, and near-term liquidity appears adequate based on available indicators even if longer-term capital needs are uncertain. | ||
RSI has reached 17, on-balance volume is declining, and the stock trades below the 200-day moving average — conditions consistent with acute seller exhaustion — yet the 200-day average itself continues rising at approximately 14% per month, indicating this may be a severe pullback within an intact long-term trend rather than a confirmed structural breakdown. Momentum breakdown | RSI recovers above 40 and price closes above the 200-day moving average within 3 months, with on-balance volume stabilizing, confirming that acute selling pressure was exhausted rather than the beginning of a new downtrend. | →Stable |
| CounterRSI at 17 can deepen further before reversing; a still-rising 200-day average provides no guarantee of mean reversion on any predictable timeline, and declining on-balance volume signals that more sellers than buyers are transacting at current levels — pressure that can persist through multiple attempted recoveries. | ||
Short interest at 30% of float — characterized as justified by the risk assessment — and implied volatility near 98% reflect deep institutional skepticism about near-term prospects and create a structurally elevated cost of carry that makes holding through clinical milestones expensive. Risk breakdown | Short interest falls below 15% of float, indicating that institutional bears have materially reduced their conviction in the downside case. | →Stable |
| Counter30% short interest in a company with an 83% analyst upside estimate and three consecutive earnings beats creates substantial potential for a short squeeze if pipeline data surprises favorably; shorts may represent the most compressed source of near-term demand if clinical results are positive. | ||
The entire investment thesis rests on a single drug candidate; a clinical failure, trial delay, or restrictive label outcome for this program would eliminate the primary source of expected value with no diversified asset base to sustain the business.
→StableBear case
- Expectation
- At least 2 pipeline programs reach Phase 2 or later within 8 quarters, reducing dependence on the lead candidate and providing an independent source of potential value.
CounterDeep focus on a single, well-characterized candidate can accelerate development timelines and allows management to concentrate clinical and commercial resources where their conviction is highest; focused development in a well-defined indication is a strategic choice, and analysts covering the program have set a consensus target 83% above the current price.
Free cash flow is negative, the Piotroski F-Score is only 3 out of 9, and there is no identified competitive moat — three conditions together meaning the business consumes capital without a demonstrated ability to generate durable returns, leaving the quality foundation extremely thin.
→StableQuality breakdown
- Expectation
- Cash runway extends without dilutive financing for at least 6 consecutive quarters while the Piotroski F-Score rises above 5, signaling improving financial health.
CounterPre-revenue clinical-stage companies are structurally loss-making; burn rates and low Piotroski scores are expected at this development stage, and near-term liquidity appears adequate based on available indicators even if longer-term capital needs are uncertain.
RSI has reached 17, on-balance volume is declining, and the stock trades below the 200-day moving average — conditions consistent with acute seller exhaustion — yet the 200-day average itself continues rising at approximately 14% per month, indicating this may be a severe pullback within an intact long-term trend rather than a confirmed structural breakdown.
→StableMomentum breakdown
- Expectation
- RSI recovers above 40 and price closes above the 200-day moving average within 3 months, with on-balance volume stabilizing, confirming that acute selling pressure was exhausted rather than the beginning of a new downtrend.
CounterRSI at 17 can deepen further before reversing; a still-rising 200-day average provides no guarantee of mean reversion on any predictable timeline, and declining on-balance volume signals that more sellers than buyers are transacting at current levels — pressure that can persist through multiple attempted recoveries.
Short interest at 30% of float — characterized as justified by the risk assessment — and implied volatility near 98% reflect deep institutional skepticism about near-term prospects and create a structurally elevated cost of carry that makes holding through clinical milestones expensive.
→StableRisk breakdown
- Expectation
- Short interest falls below 15% of float, indicating that institutional bears have materially reduced their conviction in the downside case.
Counter30% short interest in a company with an 83% analyst upside estimate and three consecutive earnings beats creates substantial potential for a short squeeze if pipeline data surprises favorably; shorts may represent the most compressed source of near-term demand if clinical results are positive.
TrendMatrix Research · core thesis
Engine thesis — one sentence
Celcuity presents a high-risk, high-optionality profile: 58.8% of upside headroom to the analyst consensus target with an 8.4-to-1 reward-to-risk ratio reflects strong analyst conviction in the lead pipeline program, but the company burns cash with negative free cash flow, quality scores among the weakest in the universe, a price that has plunged to an RSI of 17, and 30% short interest — a combination that demands a successful clinical catalyst to bridge the gap between current price and the fundamental case.
Falsifiable statement — pillar-level invalidators below. Engine-derived; not personalized advice.
Per-dimension breakdown
Quality
1.4/10data confidence 100%| Component | Sub-score |
|---|---|
| ROA | 0.0 |
| Gross margin | 0.0 |
| Op margin | 0.0 |
| Net margin | 0.0 |
| Current ratio | 5.0 |
| FCF quality | 0.0 |
| Moat | 3.2 |
| Piotroski F | 3.3 |
- ▸Cash-burning (FCF negative)
- ▸No competitive moat
- ▸Weak Piotroski F-Score: 3/9
- ▸Quality concerns
Growth
10.0/10data confidence 33%| Component | Sub-score |
|---|---|
| EPS growth | 10.0 |
Momentum
6.4/10data confidence 100%| Component | Sub-score |
|---|---|
| RSI | 3.6 |
| MACD | 10.0 |
| OBV | 10.0 |
| MA position | 7.0 |
| Volume | 1.3 |
- ▸Overbought (RSI 88)
- ▸Volume accumulation (rising OBV)
- ▸Above 200-day MA
Sentiment
7.9/10data confidence 100%| Component | Sub-score |
|---|---|
| Analyst rating | 8.3 |
| Price target | 9.5 |
| erm sentiment | 5.5 |
- ▸Analyst upside: 49%
Insider
3.9/10data confidence 75%| Component | Sub-score |
|---|---|
| materiality | 4.5 |
| insider conviction | 2.0 |
| holder change | 5.3 |
- ▸Modest insider selling — $4,781,181 (0.091% of mkt cap)
Peer rank
2.5/10data confidence 80%| Component | Sub-score |
|---|---|
| value rank | 5.0 |
| quality rank | 0.0 |
| growth rank | 5.0 |
Technical
2.4/10data confidence 100%| Component | Sub-score |
|---|---|
| bollinger | 0.0 |
| support resistance | 0.1 |
| 52w position | 4.3 |
| gap | 5.0 |
Risk (lower is worse)
3.6/10data confidence 100%| Component | Sub-score |
|---|---|
| short interest | 0.2 |
| days to cover | 4.2 |
| volatility | 1.2 |
| put call | 9.8 |
| implied vol | 0.0 |
| beta | 10.0 |
| debt equity | 0.0 |
- ▸High short interest justified: 33%
- ▸High IV: 93%
- ▸Concentration risks: 1 HIGH (10-K Item 1A — sized via position_sizing, validated via buy_confidence)
Catalyst
6.0/10data confidence 100%| Component | Sub-score |
|---|---|
| erm | 5.0 |
| earnings history | 6.7 |
| earnings timing | 5.0 |
| surprise avg | 7.4 |
- ▸Strong earnings: 3B/1M
How the verdict was assembled
Engine trigger
Quality below minimum threshold.
Engine technical detail
verdict_path:
L1:HARD_BLOCKPassed (7)
- MOMENTUM:6.4>=5.5
- ASYMMETRY:2.0>=1.5
- INSIDER:OK
- NEWS_EVENTS:NONE_RECENT
- EARNINGS_PROXIMITY:41d clear
- SEMI_CYCLE_PEAK:CLEAR
- MATERIALS_CYCLE_PEAK:CLEAR
Failed (0)
none
Warning (1)
- 8K_CSUITE_CHANGE:5.02 (officer departure/appointment)
Reward-to-Risk
1.96
Upside
+29.5%
Downside
15.0%
Sizing output
AVOID
Setup— — No clear chart pattern; technical signals are mixed
EdgeNo clear edge — No clear edge identified
SuitabilitySpeculative — Binary industry: Biotechnology
Investment implication
The L1 gate blocked the positive-verdict path: a hard-floor threshold was breached, so dimensional pillars — including Growth at 10.0 could not lift the engine output above the verdict floor.
The strongest dimensions are Growth at 10.0, Sentiment at 7.9, and Momentum at 6.4; the weakest are Quality at 1.4, Technical at 2.4, and Peer rank at 2.5. The V9 engine cleared all gates with 1 warning, producing an asymmetric reward-to-risk of 1.96 and an engine sizing output of AVOID.
What would invalidate the thesis
Falsifying conditions — when triggered, the corresponding pillar's thesis is invalidated.
- P1Single Pipeline Asset Concentration
Trip ifAt least 2 pipeline programs reach Phase 2 or later within 8 quarters.
- P2Cash Burning Quality Near Floor
Trip ifFree cash flow rises above $0 for 2 consecutive quarters.
- P3Capitulation Risk Vs Rising Long Term Trend
Trip if200-day moving average slope turns negative and price remains below the 200-day moving average for more than 60 consecutive trading days.
- P4High Short Interest Institutional Skepticism
Trip ifShort interest falls below 15% of float.